Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 217

Sort by

Sort Order Select

Journal Articles

Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

Blood (2024) 144 (Supplement 1): 889.

https://doi.org/10.1182/blood-2024-202995

Published: 2024

Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Blood (2024) 144 (Supplement 1): 772.

https://doi.org/10.1182/blood-2024-200336

Published: 2024

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Blood (2024) 144 (Supplement 1): 770.

https://doi.org/10.1182/blood-2024-203818

Published: 2024

Journal Articles

Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Annemiek Broijl, Fredrik Schjesvold, Abdel el Yaakoubi, Djamila Issa, Sonja Zweegman, Kon-Siong Jie, Mario Boccadoro, Roman Hajek, Bronno van der Holt, Ruth Wester, Pieter Sonneveld

Blood (2024) 144 (Supplement 1): 676.

https://doi.org/10.1182/blood-2024-209809

Published: 2024

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Initial Phenotypic Characterization of Anti-SEM4A CAR T Cells

Piotr Celichowski, Quynh Nhu Nguyen, Sandra Charvatova, Michal Durech, Jana Kotulova, Eva Radova, Ondrej Venglar, Tomas Jelinek, Roman Hajek, Michal Simicek

Blood (2024) 144 (Supplement 1): 7145.

https://doi.org/10.1182/blood-2024-206766

Published: 2024

Journal Articles

The Evaluation of a Point-of-Care Hematology Analyzer Hemoscreen for Abnormal Blood Samples

Katarina Hradska, Martin Pulcer, Michaela Skorupova, Tereza Popkova, Veronika Kelbichova, Martin Augustynek, Roman Hajek

Blood (2024) 144 (Supplement 1): 7632.

https://doi.org/10.1182/blood-2024-205824

Published: 2024

Journal Articles

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Blood (2024) 144 (Supplement 1): 487.

https://doi.org/10.1182/blood-2024-199550

Published: 2024

Journal Articles

Real World Experience with Venetoclax-Based Therapy in Acute Myeloid Leukemia in the Czech Republic

Barbora Dluhosova, Benjamin Visek, Jan Valka, Martin Cernan, Anna Jonasova, Jan Novak, Jiri Sramek, Jana Stevkova, Jolana Mertova, Tomas Szotkowski, Lubomir Minarik, Michal Karas, Roman Hajek, Zdenek Koristek

Blood (2024) 144 (Supplement 1): 7935.

https://doi.org/10.1182/blood-2024-209305

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Markus Rückert, Guillaume Azarias, Mamta Garg, Ceri Bygrave, Hannah Belcher, Clare Hague, Kristina Bardenheuer, Wout Vekemans, Morten Salomo, Blanca Gros Otero, Nolen Perualila, Michel Van Speybroeck, Joris Diels, Vladimir Maisnar, Ivan Špička, Roman Hájek

Blood (2024) 144 (Supplement 1): 2388.

https://doi.org/10.1182/blood-2024-201692

Published: 2024

Journal Articles

Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment

Blood (2024) 144 (Supplement 1): 1887.

https://doi.org/10.1182/blood-2024-206798

Published: 2024

Journal Articles

Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2024-205481

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Blood (2024) 144 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2024-207087

Published: 2024

Journal Articles

Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Tomas Jelinek, Serafim Nenarokov, Tereza Sevcikova, Eva Radova, Ondrej Venglar, Veronika Kapustova, Lucie Broskevicova, Jan Vrana, Ludmila Muronova, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Michal Simicek, Bachisio Ziccheddu, Benjamin Diamond, Francesco Maura, Ola Landgren, David Zihala, Roman Hájek

Blood (2024) 144 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2024-206825

Published: 2024

Journal Articles

Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets - Analysis of the Czech Myeloma Group

Jiri Minarik, Luděk Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Stork Martin, Jan Straub, Vojtech Latal, Dominik Fric, Vladimir Maisnar, Roman Hajek

Blood (2024) 144 (Supplement 1): 2378.

https://doi.org/10.1182/blood-2024-200014

Published: 2024

Journal Articles

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients - Czech Multi-Center Real World Evidence Analysis

Martin Stork, Jakub Radocha, Tomas Jelinek, Ivan Spicka, Tomas Pika, Alexandra Jungova, Jan Straub, Jiri Minarik, Ivanna Boichuk, Dominik Fric, Denisa Novakova, Tereza Popkova, Lenka Polcerova, Vladimir Maisnar, Ludek Pour, Roman Hajek

Blood (2024) 144 (Supplement 1): 5156.

https://doi.org/10.1182/blood-2024-202002

Published: 2024

Journal Articles

Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients

Ondrej Venglar, Eva Radova, David Zihala, Ivana Tvrda, Ludmila Muronova, Veronika Kapustova, Lucie Broskevicova, Jan Vrana, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Tereza Sevcikova, Michal Kascak, Milan Navratil, Zdenek Koristek, Roman Hajek, Tomas Jelinek

Blood (2024) 144 (Supplement 1): 1962.

https://doi.org/10.1182/blood-2024-204692

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Journal Articles

A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

Tereza Popkova, Jakub Radocha, Martin Stork, Jiří Minařík, Jan Straub, Alexandra Jungova, Petr Pavlicek, Tomas Jelinek, Vladimir Maisnar, Ludek Pour, Tomas Pika, František Sedlák, Jan Soukup, Hana Plonkova, Ludmila Muronova, Viera Sandecka, Petra Krhovska, David Zihala, Roman Hajek

Blood (2024) 144 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2024-211224

Published: 2024

Journal Articles

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Blood (2024) 144 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2024-201783

Published: 2024

NARROW

Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Initial Phenotypic Characterization of Anti-SEM4A CAR T Cells

The Evaluation of a Point-of-Care Hematology Analyzer Hemoscreen for Abnormal Blood Samples

Real World Experience with Venetoclax-Based Therapy in Acute Myeloid Leukemia in the Czech Republic

Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment

Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets - Analysis of the Czech Myeloma Group

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients - Czech Multi-Center Real World Evidence Analysis

Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only